搜尋結果
Relief of pain & inflammation in lumbago (muscular & fascial lumbago, spondylosis deformans, discopathy & sprain of lumbar spine), OA, humeroscapular periarthritis, tendinitis/tendovaginitis, peritendinitis, humeral epicondylitis, myalgia & post-traumatic swelling/pain.
Dosage/Direction for Use. Adult Improvement of abdominal symptoms due to gas in GIT 120-240 mg daily divided in 3 doses. Elimination of foamy mucus in the stomach prior to gastric endoscopy 40-80 mg w/ 10 mL water at 15-40 min prior to test. Elimination of gas in the intestine prior to abdominal x-ray 120-240 mg daily divided in 3 doses 3-4 ...
Usual initial dose: 10-20 mg once daily. Dose range: 5-40 mg once daily. 40 mg dose should be used only for patients who have not achieved LDL-C goal w/ 20 mg dose. HeFH Childn & adolescent 10-17 yr 5-20 mg/day. Max: 20 mg/day. Homozygous familial hypercholesterolemia Adult Initially 20 mg once daily. Asian patient Initially 5 mg once daily.
Dosage/Direction for Use. Asthma Adult & adolescent ≥12 yr 1 inhalation of 100/25 mcg once daily, may be increased to a max dose of 200/25 mcg once daily. COPD Adult ≥18 yr 1 inhalation of 100/25 mcg once daily. Click to view Relvar Ellipta detailed prescribing information.
Indications and Dosage. Adult: As loperamide hydrochloride cap: Initially, 4 mg daily; adjusted until 1-2 solid stools a day are obtained, which is usually achieved with maintenance dose of 2-12 mg daily. Max: 16 mg daily. As loperamide hydrochloride oral solution: Initially, 4-8 mg daily in divided doses, may be adjusted depending on response.
Primary hypercholesterolaemia (heterozygous familial or nonfamilial) & mixed dyslipidaemia Adult Initial dose: 10 or 20 mg once daily; 40 mg daily in patients requiring >45% reductions in LDL-cholesterol. Maintenance dose: 10-80 mg once daily. Heterozygous familial hypercholesterolaemia Childn ≥10 yr 10 mg once daily.
2023年9月3日 · The updated cardiovascular disease (CVD) prediction algorithm SCORE2 can be used to estimate the 10-year CVD risk in individuals without diabetes or CVD in the Asia Pacific/Middle East region, according to a study presented at ESC 2023.
